Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.

Kenvue Goes Boom - Now What?

Hudson Technologies

Kinross Gold

Nu Holdings

AT&T

Teva Pharmaceutical

Warner Bros Discovery Inc

Cheap stocks are often cheap for a reason. That bit of investing wisdom underscores the need to perform due diligence on a company and not just buy it because the stock trades at a low price.

The 7 Best Under $20 Stocks to Buy in August 2024

Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.

S&P 500 Gains and Losses Today: Kenvue Soars on Band-Aid Maker's Strong Outlook

Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript

Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations.

Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance

Among the key stocks in focus in today's session is Kenvue (NYSE: KVUE ). The company, which was spun off from parent Johnson & Johnson (NYSE: JNJ ) almost exactly one year ago, is seeing strong traction in the market today.

Kenvue News: Why Investors Are Loving KVUE Stock This Week

Amcor Plc

Franklin Resources

Hormel Foods

“Dividend Aristocrats… in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years.“- Kiplinger.. 67 Aristocrats, screened as of August 2, 2024, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 8.12%-27.1% topped by CVX & TGT.

4 Dividend Aristocrats To Buy In August And More To Watch

Shares of the Band-Aid parent are on track for their largest daily percent increase on record.

Kenvue Is the S&P 500 Stock After Earnings. Here's Why.

Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics

Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.

Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates

Shares in Kenvue Inc (NYSE:KVUE) were up 9% in pre-market trading after the company exceeded Wall Street's expectations for second-quarter profit and revenue. The consumer health company, spun off from Johnson & Johnson (NYSE:JNJ) last year, reported strong sales in its essential health products unit, which includes Tylenol, Listerine, and Neutrogena.

Kenvue stock up 9% after earnings beat; consumer health stars

Shares of Kenvue Inc. KVUE, -3.35% jumped 3.4% in premarket trading Tuesday, after the parent of consumer health brands including Band-Aid, Tylenol and Listerine reported second-quarter earnings that beat expectations, boosted by productivity gains and higher pricing. Net income fell to $58 million, or 3 cents a share, from $430 million, or 23 cents a share, in the year-ago period.

Kenvue's stock jumps as Band-Aid, Tylenol parent beat profit and sales expectations

Kenvue beat Wall Street estimates for second-quarter profit and revenue on Tuesday, helped primarily by better-than-expected sales in its essential health products unit that sells brands including Band-Aid, Listerine and Carefree.

Listerine maker Kenvue beats estimates on strong essential health product sales

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal second quarter ended June 30, 2024.

Kenvue Reports Second Quarter 2024 Results

Coca-Cola

PepsiCo

Coca-Cola has turned its business around, and the stock just hit an all-time high. Pepsi's growth is slowing, but the stock remains a great value.

All It Takes Is $10,000 Invested in Coca-Cola and Each of These 2 Dividend Kings to Generate Over $1,000 in Passive Income per Year

Kenvue stock has not participated in the recent rotation into value stocks. It trades at a forward P/E of 16 and a free cash flow yield of 6%. Such a valuation is indeed rare to find in the - typically overvalued - consumer staples sector, as is a starting dividend yield of 4.4%. In this article, I explain the main reasons for my growing enthusiasm and why I expect to initiate a long position in KVUE stock shortly.

Is Kenvue The Next Big Dividend (Growth) Stock?

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announces the implementation of a Board of Directors succession process.

Kenvue Announces Board Changes with Two New Independent Directors

Brookfield Renewable Partners

Mid-America Apartment Communities

Williams

Yields are higher right now, thanks to higher interest rates. With the Fed poised to cut rates, these higher yields might not last much longer.

4 Top Dividend Stocks Yielding Over 4% to Buy Hand Over Fist Right Now for Decades of Passive Income

Realty Income Corp

T. Rowe Price Group

24/7 Insights The Dividend Aristocrats offer some of the very passive income solutions.

5 High-Yield Dividend Aristocrats Offer Investors a Passive Income Grand Slam

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced a 2.5% increase in its quarterly dividend as its Board of Directors declared a $0.205 per share dividend on its common stock.

Kenvue Increases Quarterly Cash Dividend

Kraft Heinz

TELUS

In recent trading days, investors have been rotating from growth stocks to value stocks, creating a fertile ground for overlooked dividend stocks. With the spotlight having shone brightly on growth stocks during last year's rally, many dividend stocks have been left in the shadows.

3 Dividend Stocks to Buy at a 52-Week Low

Fortis

United Bankshares

24/7 Insights The Dividend Kings provide dependable passive income streams.

5 Overlooked Dividend Kings to Buy Hand-Over-Fist Now

Coty

Darling Ingredients

Lamb Weston Hlds

Medifast

Monster Beverage

Newell Brands

For the last two years, investors in consumer staples stocks saw every tiny step forward smacked down by two large steps back. Therefore, the 900+-point gain in the Dow Jones Industrial Average (DJIA) the week of July 15 was noteworthy.

7 Consumer Staples Stocks to Buy at a 52-Week Low in July

ARMOUR Residential REIT

Eagle Point Credit

Enterprise Products Partners

NextEra Energy

Orchid Island Capital

Oxford Lane Capital

PIMCO Dynamic Income Fund

Prospect Capital

Ready Capital Corp

Triplepoint Venture Growth BDC

Trinity Capital

TotalEnergies SE

Verizon

Prior to June 30, 2024, my REaders mentioned 40 equities in their comments on my articles. Some bad news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: VZ, EPD, ECC, OXLC, NEP, TTE, RC, KVUE, ORC, and TPVG averaged 21.11% net gains from reader data collected 7/12/24. Ten analyst-target-augured June TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: NEP, RC, O, ORC PFE, VZ, EPD, TPVG, TTE, and KVUE, boasting a 12.02% average target price upside estimate.

Readers Identify 30 Ideal June Dividend Buys Out Of 40 Nods

Federal Realty Investment Trust

Altria

Northwest Natural Gas

Universal Corp

24/7 Insights The Dividend Kings have all raised their dividend for at least 50 years.

6 Dividend Kings to Buy in July That Deliver Huge Passive Income

News for Kenvue Stock (KVUE)